UBS Group: Raises Moderna Target Price from $50 to $150

Odaily News, UBS Group stated it has raised the price target for Moderna (MRNA.O) from $50 to $150. Previously reported, Moderna's personalized mRNA cancer vaccine, developed in collaboration with Merck, achieved significant success in a Phase 3 clinical trial for high-risk melanoma, marking the world's first mRNA cancer therapy proven effective in a large-scale Phase 3 trial. Following the announcement, Moderna's stock price surged nearly 177% in a single day.